VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Not Recruiting

Trial ID: NCT01289210


This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Official Title

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Stanford Investigator(s)

Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD

Moghadam Family Professor

Manali Patel
Manali Patel

Associate Professor of Medicine (Oncology)


Major Inclusion Criteria:

* low grade B cell lymphoma
* 1 or more sites of disease appropriate for intratumoral injection
* measurable disease other than the injection site
* Performance Status of 1 or better
* Adequate bone marrow, renal and hepatic function
* No active autoimmune disease or systemic immunosuppressive drugs
* Life expectancy \> 4 months

Exclusion Criteria:

* Known HIV
* Known brain metastases
* Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
* Anticoagulation therapy other than 325mg QD ASA
* Significant cardiovascular disease
* Pregnant or nursing


drug: VTX-2337 plus radiotherapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lori Richards

New Trial Alerts